#ASH25 thankfully we didn’t put our eggs in one CANOVA basket! Hang Quach continuing to show excellent data for BCL2 inhibition in #MMsm with t(11;14), this time with sonrotoclax. Plays nicely in the sandbox with K!

Excellent #ASH25 ASH article by Ben Derman about MRD-guided discontinuation of #MMsm maintenance therapy based on data we have currently (while we await SWOG S1803). I've been doing 2 years of len maintenance before these discussions... maybe I should start at 1!

IMMUNOPLANT: Linvo x 4-6 cycles for patients with MRD positivity following induction. Patients then resumed lenalidomide. Essentially 100% MRD negativity rate following linvo consolidation and at 6 months after completion of linvo. This is really a remarkable result and

Oh wow - this is excellent! Just now at #ASH25 and same-day published in Journal of Clinical Oncology: AL-ISS for amyloidosis staging! Snippet below. In brief, GLS a central part of this. Further away from -18% (and in particular, -9% or worse) is independently worse. Congrats to all authors!!

The main conclusion from the #Paradigm #plenary Vyxeos is dead for secondary / high risk AML (we already knew this)! Too toxic compared to HMA+ven #ASH25

I worked with the team taking care of SAA patients on Omidubucel at NIH. I think there's something there.

Congrats!

So happy to see this and proud to have briefly contributed to taking care of these patients at the NIH!

At #ASH25, Caner Saygin, MD, presents data from an ongoing Phase I/II trial investigating the LPVd regimen as a novel strategy to improve outcomes in patients with relapsed/refractory T-ALL/LBL. ⁦University of Chicago Hematology/Oncology⁩ ⁦UChicago Leukemia Program⁩ ⁦University of Chicago Hem/Onc Fellows⁩

Great listen!

How do I report a bug for the new X Android beta app?

ASH25 d1 vs d4

#ASH25 #mmsm ASH Oral-myeloma Danish ABCD Study-prophylactic Tocilizumab RW data ➡️ prophylactic Tocilizumab decreased both G1 and G2 CRS (69% to 7.5%)👇 ➡️No difference in efficacy between both groups

From #ASH25 & Journal of Clinical Oncology pub by awechalekar et al about AL-ISS staging... 🚨 In AL amyloid, start asking now for complete TTEs with speckle / GLS! I learned about GLS from my mentor Sandy Wong, but Saurabh Zanwar's excellent tweetorial below explains this for everyone 🙏🏽

Check our viewpoint published JAMA #MedEd Abstract Factory—Research Culture Harming Medical Education The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs,

How does an embryo reliably "compute" its form - "cell by cell" - using only local interactions and mechanics, yet produce a precise global body plan? I’m excited to share our Nature Methods paper "MultiCell: geometric learning in multicellular development", presenting

S2213 asks whether SCT adds value after modern ind in good-risk AL. At best, SCT may modestly improve PFS or MRD depth not OS. But tx interruption & toxi remain concerns, parti with cardiac AL. In AL, rapid and sustained LC suppression may matter more than maximal cytoreduction